Anti-EGFR monoclonal antibody-Y-90/Re-188

Drug Profile

Anti-EGFR monoclonal antibody-Y-90/Re-188

Alternative Names: RadioTheraCIM; RadioTheraCIM h-R3; Rhenium 188 TheraCIM; Yttrium 90 RadioTheraCIM

Latest Information Update: 17 Jan 2011

Price : $50

At a glance

  • Originator CIMYM
  • Class Antineoplastics; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Epidermal growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Glioma

Most Recent Events

  • 17 Jan 2011 Discontinued - Phase-I for Glioma in Cuba (unspecified route)
  • 17 Jan 2011 Discontinued - Phase-I for Glioma in Italy (unspecified route)
  • 13 Sep 2005 This compound is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top